A pilot controlled trial of transdermal nicotine in the treatment of attention deficit hyperactivity disorder

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

Who Took Part

PubMed indexes the participants as teenagers, both men and women.

There was a three-day washout period of all psychotropic medication followed by a one-week treatment period.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and pilot study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.

It is described as a pilot, a small early test of whether a larger Therapeutic nicotine (patch, non-peptide) study would be practical.

What Was Measured

Topics PubMed links to this paper include Administration, Cutaneous, Attention Deficit Disorder with Hyperactivity, Nicotine and Pilot Projects.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2002 (The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page.